Trial Profile
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Darinaparsin (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics
- 18 Jul 2012 Additional trial location (USA) added as reported by ClinicalTrials.gov.
- 18 Jul 2012 Planned end date changed from 1 Sep 2010 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 01 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.